NaF PET/CT OPTIONAL SUB-STUDY ELIGIBILITY CRITERIA
All disease must be assessed and documented on the S FDG-PET/CT assessment form
Patients unable to have an FDG-PET scan, either through insurance coverage, patient decision or other reason are not eligible for this study
Patients unable to have an FDG-PET/CT scan, either through insurance coverage, patient decision or other reason are not eligible for this study
PHASE II INCLUSION CRITERIA: Patients with tumor tissue uptake during NETSPOT PET that is equal to or higher than that in normal hepatic tissue (grade >= ) will be eligible; it is recommended that NETSPOT PET be obtained before initiation of chemotherapy, but NETSPOT PET obtained during or after completion of chemotherapy could be used for screening purpose
Patients with AST or ALT or alkaline phosphatase > ULN are eligible for inclusion in the study if liver imaging (CT, MRI, PET-CT, or PET scan) performed within  days prior to randomization does not demonstrate metastatic disease and the requirements in criterion (just above) are met.
Tany N- or T- N as determined by endoscopic ultrasound (EUS) and PET/CT; all palpable or CT/PET visible lymph nodes outside the usual surgical field must be biopsy-proven negative for cancer
All patients must have initial PET/CT scans to document no evidence of metastatic or unresectable squamous cell cancer
T- N as determined by EUS and PET/CT
Patients must have measurable or evaluable disease that is FDG avid with standardized uptake value (SUV) >  on PET/CT
After chemotherapy, patients must be restaged prior Step  registration using the same diagnostic work-up as required pre-chemotherapy; repeat PET/CT or bone scan is not required; patients must have:\r\n* History/physical examination within  days of Step  registration\r\n* No central nervous system (CNS) metastases (repeat MRI required) within  days prior to Step  registration\r\n* No progression in any site\r\n* Radiographic partial or complete response to chemotherapy in at least one disease site within  days prior to Step  registration\r\n** If PET/CT was obtained prior to chemotherapy, either a repeat PET/CT or CT of the chest and abdomen with contrast can be obtained for response assessment\r\n** Patients who underwent resection for limited-stage SCLC prior to chemotherapy and have no radiographically evident disease for response assessment remain eligible if post-chemotherapy imaging demonstrates no progression
Measurable disease (at least  lesion of >= . cm in diameter) as detected by CT or the CT images of the PET/CT; NOTE: patients with Waldenstrom macroglobulinemia are not required to have measurable disease by CT or PET/CT if monoclonal protein is detectable by serum protein electrophoresis and/or immunoglobulin M (IgM) level is at least  times upper limit of normal
CLL diagnosis confirmed as have biopsy proven Richters transformation; NOTE: both untreated and previously treated patients in this category can be enrolled as long as measurable disease can be detected by PET/CT or CT (>=. cm in diameter)
PET/CT-guided cryoablation criteria-cohort :\r\n* Patients must have a mass that is well visualized under PET/CT; tumors that are not clearly seen by MRI but showing on PET/CT will be ablated with PET/CT guidance
PET/CT-guided cryoablation exclusion criteria-cohort :\r\n* PET/CT is contraindicated in the pregnant patient\r\n* Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with PET/CT guidance
Diabetes must be controlled prior to PET-CT scanning (blood glucose <  mg/dL)
Creatinine =< . (within  days of PET imaging)
Patient must have a least one lesion greater than  cm on standard imaging (CT, MR, octreotide, or dotatate imaging) that is judged amenable to AMT-PET
Eligible and consent signed for imaging with AMT PET under protocol -
Stage IIIB, or distant metastases (including malignant pleural effusion) identified on PET-CT scan or biopsy (PET abnormalities that are negative for malignancy on biopsy will be considered on a case by case basis
A PET/CT scan is required within  weeks (plus/minus  week) of study registration. Any lymph node suspected of harboring disease based on its shape, size, or PET standardized uptake value (SUV) should be discussed by treating physician and diagnostic radiologist
The following mandatory staging studies must be done within  weeks before study registration:\r\n* PET/CT scans of both lungs, the mediastinum, adrenal glands and rest of the body; primary tumor dimension will be measured on diagnostic CT and again on simulation CT using the lung window setting\r\n* Mediastinoscopy or endobronchial ultrasound -guided biopsy of the mediastinal lymph nodes is recommended and required for any patients with PET/CT or CT findings suggesting lymph node involvement\r\n* Brain magnetic resonance imaging (MRI) or CT scan if symptoms or signs suggest brain metastases\r\n* Invasive mediastinal staging: For all patients with CT or PET evidence of hilar involvement (level ) or with mediastinal lymph nodes > . cm in the shortest diameter or clinically suspicious by treating physician and/or radiologist, disease must be staged by cervical mediastinoscopy, esophageal endoscopic ultrasound-guided biopsy, or endobronchial ultrasound-guided biopsy
Cutaneous metastases diagnosis confirmed prior to consent by preferred institutional methodology which may include, but is not limited to: biopsy ?  months; conventional radiography; imaging techniques to include bone scan (scintigraphy), computed tomography (CT), fluorodeoxyglucose-positron emission tomography (FDG-PET)/CT), magnetic resonance imaging (MRI), F-fluoromisonidazole-(F-FMISO) PET/CT, fluorothymidine-(FLT) PET/CT, fluoroestradiol-(FES) PET/CT, and PET/MRI;
Inability to undergo PET-CT
Has known metastatic disease; staging CT C/A/P or PET/CT will be mandatory no more than  days prior to enrollment to evaluate for the presence of metastatic disease
>=  lesion detectable on CT, MRI, fludeoxyglucose F- (FDG) PET-CT, or PET-MRI
PET-positive disease by Lugano classification
Uncontrolled diabetes (i.e., will interfere with the performance of the FDG PET/CT scans)
pre-operative imaging (chest CT and PET-CT
Patients must be willing to undergo FLT PET/CT or NaF PET/CT scans for the investigational component of this trial and have no known allergies to FLT or NaF
Documented (signed) informed consent; the patient, family member and transplant staff physician (physician, nurse, and social worker) meet at least once prior to starting the transplant procedure; during this meeting all pertinent information with respect to risks and benefits to donor and recipient will be presented; alternative treatment modalities will be discussed:\r\n* A. No Research Imaging  for patients for whom one or more of the following applies:\r\n** Is a minor (<  years of age)\r\n** Acute lymphoblastic leukemia (ALL) diagnosis\r\n** Does not agree to optional imaging (WF-MRI, DECT)\r\n* B. With Research Imaging  all of the following must apply:\r\n** Adult (>=  years of age)\r\n** Acute myeloid leukemia AML diagnosis\r\n** Agree to optional imaging: WF-MRI and DECT\r\n** Do not agree to optional FLT-PET, or there are no FLT-PET slots available\r\n* C. With Research Imaging plus FLT-PET\r\n** Adult (>=  years of age)\r\n** AML diagnosis\r\n** Agrees to optional imaging: WF-MRI and DECT\r\n** Agrees to optional FLT-PET\r\n** FLT-PET accrual remains open
RANDOMIZED PHASE II (ARMS K AND L): Patients must have measurable disease; baseline measurements and evaluations must be obtained within  weeks of registration to the study; abnormal PET scans will not constitute evaluable disease unless verified by a diagnostic quality CT scan; patients must use the same imaging modality (CT or PET/CT) throughout the study
MRI/CT/PET of the brain within  days of lymphodepletion
Fludeoxyglucose F  (FDG)-avid disease by FDG-PET/CT and measurable disease of at least . cm by CT
Able to undergo diagnostic PET/computed tomography (CT) or PET/CT simulation
Known incompatibility to CT or PET scans.
Systemic corticosteroids between pre-PET and post-PET evaluation and biopsy
Patients whose only nodal disease is cystic and not PET-avid
Imaging of abdomen (CT or CT colonogram or MRI or PET or Ultrasound) within  months prior to randomization
Diagnostic quality, cross sectional imaging of the thorax within  days prior to registration; -F-FDG-PET/CT or conventional CT are acceptable.
Patient must be able to tolerate imaging requirements of an -FDG-PET-CT scan
Patients with hypermetabolic para-aortic disease identified on baseline -FDG-PET-CT
PHASE II: The patient meets the criteria required for the imaging study in which the site is participating:\r\n* NOTE: Eligibility for participating in either imaging sub-study will depend on the availability of the imaging sub-study at a particular institution\r\n* For participation in the FDG-PET sub-study:\r\n** Patients must NOT have poorly controlled diabetes (defined as fasting glucose level >=  mg/dL) despite efforts to improve glucose control by fasting duration and adjustment of medications\r\n** Patient must NOT weigh more than the maximum weight limit for the PET table\r\n** Patients must have an evaluable lesion of >  mm in size on standard practice imaging study as assessed by site (either primary pancreas mass or metastasis)\r\n* For participation in the FLT-PET sub-study:\r\n** Patients must be able to lie still for a . hour PET scan.\r\n** Patient must NOT have a history of allergic reaction attributable to compounds of similar chemical or biologic composition to F-fluorothymidine\r\n** Patient must NOT weigh more than the maximum weight limit for the PET table\r\n** Patients must have an evaluable lesion in the pancreas >  mm in size on standard practice imaging study as assessed by site (lesion must be likely primary adenocarcinoma of the pancreas that is not primarily fibrotic or mucinous in nature)
FDG-PET/CT scan for staging and RT plan within  weeks prior to registration
Able to tolerate PET/CT imaging required to be performed at an American College of Radiology (ACR) Imaging Core Laboratory (Lab) qualified facility
Stage TN-, T-N-, according to the American Joint Committee on Cancer (AJCC) th edition staging, based on the following minimum diagnostic work-up:\r\n* Chest/abdominal/pelvic computed tomography (CT) or whole-body positron emission tomography (PET)/CT (NOTE: if CT is performed at this time point, whole-body PET/CT will be required prior to step  registration; PET/CT of skull base to mid-thigh is acceptable) (NOTE: if adenopathy is noted on CT or whole-body PET/CT scan, an endoscopic ultrasound is not required prior to STEP  registration as long as adequate tissue has been obtained for central HER testing)\r\n* Patients may have regional adenopathy including para-esophageal, gastric, gastrohepatic and celiac nodes; if celiac adenopathy is present, it must be =<  cm\r\n* Patients with tumors at the level of the carina or above must undergo bronchoscopy to exclude fistula
Interim PET/CT scans must have been submitted for centralized review
Patients must have at least one measurable lesion that can be followed for response assessment on baseline imaging obtained no more than  days prior to beginning study therapy. Baseline and follow up radiological disease assessment must include bone scans performed with either Technetium-m labeled diphosphonates or Fluorine- sodium fluoride PET or PET/CT, as per the local standard of care for patients with prostate cancer.
PET/CT
Patients must have received baseline FDG-PET/CT +/- CT with contrast within  month +/-  weeks prior to study entry, and should have no contraindications to PET or CT imaging
Patients with at least one target lesion amenable to serial static and dynamic FLT-PET/CT imaging will be mandated to have correlative FLT-PET/CT imaging per the study schema for a target of  patients with a maximum of  patients
Evidence of metastatic disease on PET, CT, and/or MRI performed within  weeks of enrollment
Fluorodeoxyglucose (FDG)-avid disease by PET and measurable disease of at least . cm by CT
MRI of the pelvis and/or PET-CT within  months before registration
Residual FDG-PET activity defined as Deauville  or  on a PET-CT within  and  weeks post the last dose of front line therapy
Disease progression: FDG avid malignancy that is classified as an FDG PET non-responder\r\n* PET non-responders are defined as having < % reduction in the FDG uptake of the primary tumor when compared to baseline
Patients must have an avid primary tumor with an standardized uptake value (SUV) of >=  on baseline (F) FDG-PET/computed tomography (CT) imaging
FDG PET-CT (disease) positive baseline scan with measurable disease.
Gross disease in the retrostyloid (high level II) or retropharyngeal lymph node regions by CT or PET/CT
One or more measurable (> . cm in longest dimension) disease sites on CT (preferably PET/CT) or, if CT is contraindicated, MRI (preferably PET/MRI) scans.
Patients are eligible with untreated squamous, adenosquamous, or adenocarcinoma cancers of stage IB-IVA carcinoma of the uterine cervix or stage II-IVA vaginal carcinoma not amenable to curative surgical resection; pathological verification of diagnosis must be obtained and recorded; the presence or absence of para-aortic lymph node metastasis will be based on pre-therapy F-FDG PET/CT; if the baseline F-FDG PET/CT identifies hypermetabolic para-aortic disease, such patients will not be eligible for participation; the patient must be able to tolerate the requirements for F-FDG PET/CT scanning
Patients must be considered an appropriate candidate for stereotactic body radiation therapy (SBRT); this is determined on an individualized basis, by the prospective multidisciplinary tumor board, that includes representation from surgical, radiation and medical oncology; criteria for appropriateness for SBRT include all of the following: but:\r\n* Stage I/II non-small cell lung carcinoma (NSCLC)  no evidence of distant metastases (patients with up to three lung nodules may be considered to have multiple primary lung cancer rather than metastatic lung cancer and thus will be eligible; if a lymph node(s) >=  cm and/or PET-SUV >= . is identified, biopsy must be performed (and be negative) for the patient to be eligible; patients thought to have Mb disease, or malignant pleural/pericardial effusions are not eligible\r\n* Staging including CT chest, PET/CT must be up-to-date, i.e. within  weeks prior to registration; brain imaging (contrast-enhanced magnetic resonance imaging [MRI] or CT) is suggested for all patients, but is only mandatory for patients with abnormal neurologic exam\r\n* Tumor size =<  cm in greatest dimension based upon an up-to-date CT (and/or CT/PET) within  weeks prior to enrollment onto the study; radiation therapy treatment planning imaging is acceptable)\r\n* The patient must not be a candidate for (or declines because of high risk) surgical resection because of medical comorbidity/risk; the patient must have undergone an evaluation by an experienced thoracic surgeon within  weeks prior to registration; standard justification criteria may include forced expiratory volume in  second (FEV) < % predicted; predicted postoperative FEV =< % predicted; diffusing capacity of the lung for carbon monoxide (DLCO) =< % predicted; pulmonary hypertension (estimated >=  mm Hg); poor cardiac function (ejection fraction [EF] =< %); Medical Research Council (MRC) dyspnea scale >=  (corresponds to inability to walk at least  yards without rest); baseline hypoxemia (partial pressure of oxygen [pO] =<  mg HG and/or pulse oxygen [ox] < %), baseline hypercapnea (carbon dioxide [CO] >=  mm Hg; there are also other, less objective criteria, including severe end-organ damage from diabetes/hypertension, severe atherosclerotic disease (heart, brain, aorta, peripheral artery)\r\n* Tumor(s) must be in a location/configuration such that risk of fistula is considered relatively low; this means that there can be no evidence of tumor invasion of a major (lobar/hilar) pulmonary vessel(s), aorta, vena cava, trachea or mainstem bronchus or esophagus; additional studies may be needed to assess this, including CT angiogram, MRI, bronchoscopy, esophagoscopy
Disease that can be assessed (evaluable) with imaging (CT, MRI, PET, radionuclide imaging or other imaging modality)
No clinical evidence of N, N or N lymph nodes as assessed by CT and/or PET-CT
Measurable disease by Non-Hodgkins Lymphoma Response Criteria on FDG-PET/CT; baseline measurements and evaluations must be obtained =<  days prior to registration
Fludeoxyglucose F- (FDG)-avid disease by FDG-PET/computed tomography (CT)
Radiologic confirmation of the absence of hematogenous metastasis within  weeks prior to registration; at a minimum, chest x-ray is required; CT imaging of the chest or PET/CT is acceptable
COHORT I: Patient must be able to tolerate PET/CT imaging
COHORT I: Patient must not have claustrophobia that would preclude PET/CT imaging or other contraindications to CT imaging
Inability to undergo anti--[F]FACBC PET-CT
Have a primary diagnosis, or at high clinical suspicion, of lung nodule(s) warranting surgery based on CT and/or PET imaging
Scheduled for or completed a F-FDG-PET or F-FDG-PET/CT tumor staging procedure
Treating radiation oncologist intends to incorporate Ga-PSMA- PET/CT findings into the radiotherapy plan if patient undergoes Ga-PSMA- PET/CT.
Prior prostate-specific membrane antigen (PSMA) PET/CT.
Patients with known or suspected neuroblastoma or pheochromocytoma are eligible. F-DA PET/computed tomography (CT) scanning will not be the initial imaging study in a newly diagnosed patient
Axumin PET/CT scan already performed or scheduled as best standard of care procedure for suspected disease relapse within  weeks before or after intended Ga-PSMA- PET/CT
Whole body F-FDG PET/computed tomography (CT) or I- scintigraphy within the past  days of the scheduled Ga-PSMA PET demonstrating uptake
Patients who have had active infection within  days of study enrollment that may be considered to interfere with Ga-PSMA PET imaging by the study investigators
Participant must have undergone a PET/computed tomography (CT) examination with injection of a standard dose of F-fluorodeoxyclucose (FDG) or other PET tracer with a half-life greater than one hour either for clinical or research purposes within  hrs of the proposed PET-MRI examination
Diagnostic CT or magnetic resonance imaging (MRI) as part of the PET study or performed within one month of PSMA PET
Ability to undergo standard PET imaging; an  F FDG PET/CT scan will take place within  weeks of enrollment
Patients who are too claustrophobic to undergo PET scanning
Documented results from (or scheduled to undergo) CT or MRI of the chest, abdomen and pelvis as a SOC procedure within  days of baseline investigational C-Gln PET/CT and F-FSPG PET/CT
Any condition that precludes the proper performance of PET and/or CT scan: a) Subjects who are not able to tolerate the CT contrast agent, b) Subjects with metal implants or arthroplasty, or any other objects that might interfere with the PET and/or CT analysis, c) Subjects unable to raise arms for prolonged imaging purposes, d) Subjects unable to lie still for the entire imaging time, e) Subjects weighing greater than  kg ( lb)
Patients with a body weight of  pounds or more, or a body mass index (BMI) which precludes their entry into the bore of the PET/CT scanner, because the findings will probably be compromised in image quality with CT, PET/CT and MRI.
Patients who cannot undergo PET/compute tomography (CT) scanning
Patient is able to remain still for duration of imaging procedure (approximately  minutes total for digital PET/CT)
Diagnostic CT or MRI as part of the PET study or performed within one month of PSMA PET
Previously imaged with F-DCFPyL PET/CT on >=  occasions as part of this or other study protocols
Patients with NSCLC diagnosis who have been referred for a clinical FDG PET/CT staging scan as part of their standard of care
Patient must have a PET/CT obtained within  days of having the EBUS-TBNA
Documented visceral metastases or current lymphadenopathy >  cm by standard imaging (e.g. magnetic resonance imaging [MRI], CT, ultrasound, fludeoxyglucose [FDG] PET/CT)
The time interval between F FSPG PET/CT and standard of care imaging (ie, F FDG PET/CT, diagnostic CT, or MRI) should be within  weeks (exceptions will be allowed for  weeks, if there are no other options)
Ideally, there should be no chemotherapy, radiotherapy, or immune/biologic therapy or biopsy between other imaging (PET/CTs, MRI, or diagnostic CTs) and F FSPG PET/CT scheduled or performed (exceptions by investigator discretion)
Claustrophobia interfering with MRI and PET/CT imaging
Patients with a body weight of  pounds or more or a body habitus or disability that will not permit the imaging protocol to be performed, due to the compromise in image quality on both CT and PET/CT; if the standard-of-care F-FDG/PET was of diagnostic in quality as determined by the official clinical interpretation, then this will be presumptive evidence that the patients body habitus and/or disabilities should not prevent a diagnostic quality F-FSPG PET/CT scan, either
A recognized active lung infection (this will confound the standard-of-care F-FDG PET/CT scan)
At least one site of disease outside of the liver that is seen on standard imaging (e.g. CT, bone scan, MRI, FDG PET/CT); patients with measurable or nonmeasurable disease are allowed
Baseline FDG-PET/CT scans must demonstrate at least one hypermetabolic lesion as defined by the Deauville criteria localizing to CT-defined anatomical tumor sites
Each patient must have completed conventional imaging and staging and CT (multiphase) or MRI before initiation of the investigational PET studies
Patients undergoing PET/MRI: contraindication to gadolinium contrast enhanced brain MRI (i.e., allergy to gadolinium contrast, MRI-incompatible implantable devices, GFR =<  mL/min/., and severe claustrophobia); at the discretion of the responsible physician, FDOPA-PET/CT may be performed if PET/MRI is contraindicated or unavailable; if FDOPA-PET/CT is performed, the patient must have undergone a contrast-enhanced MRI for fusion with FDOPA-PET no more than  weeks before the FDOPA-PET/CT
 or more foci of demonstrable metastases on recent imaging modalities (CT, magnetic resonance [MR], fludeoxyglucose [FDG] PET/CT)
Patients who cannot undergo PET/CT scanning
Patients who require sedation for imaging studies will be excluded from the FLT PET scan research test; they will undergo only the standard of care MRI and FDG PET scan
Clinically indicated PET/PET-CT (with or without clinically indicated diagnostic MRI)
Have one or more tumors visualized by conventional PET-CT, CT or magnetic resonance imaging (MRI) prior to the PET FMAU study; PET-CT should be within one week prior to F-FMAU
Computed tomography (CT) simulation, immobilization, MRI and PET imaging, treatment planning, and all follow-up MRI and PET scans to be performed at Mayo Clinic Rochester; Note: the actual radiation therapy treatments and follow-up other than imaging can be performed at Mayo Clinic Rochester, Northfield, LaCrosse, Mankato, Eau Claire, or Albert Lea
Patients who cannot undergo PET/CT scanning (i.e. because of weight limits, claustrophobia)
Radiologic evidence of new or progressive metastatic disease demonstrated on anatomical imaging (CT, magnetic resonance imaging [MRI], or ultrasound), bone scintigraphy, fluorine F  sodium fluoride ([F]sodium fluoride) PET, and/or fludeoxyglucose F  ([F]FDG) PET
Unable to cooperate for MRI and/or PET/CT
Participants will have had, or are scheduled to have clinical imaging evaluations which may include FDG PET CT, or CT, or MRI within  weeks of entry
Patient may have had a prior PET or PET/CT scan for staging/restaging.
Patient is able to remain still for duration of imaging procedure (approximately  minutes total for PET/CT and PET/MRI)
Clinical, laboratory, or diagnostic imaging findings on CT, MRI, and/or F-FDG PET/CT
Have one or more breast tumors visualized by conventional PET/CT, CT or magnetic resonance imaging (MRI) prior to the PET FMAU study; PET/CT should be within a week prior to -F FMAU
Have one or more breast tumors visualized by conventional PET/CT, CT or MRI prior to the PET FMAU study; PET/CT should be within a week prior to -F FMAU
Patients with a known or suspected malignancy who are receiving care from a pediatric oncologist and are already scheduled to receive an outpatient PET/CT examination
Participant with confirmed head and neck SCC:\r\n* CT and/or MR imaging has been completed within six () weeks prior to enrollment, even if the SCC diagnosis has been made via other methods, and will be submitted to American College of Radiology Imaging Network (ACRIN);\r\n* Simultaneous diagnostic CT with PET will not be excluded, but in such cases PET cannot be used as part of the criteria to define the N neck as required for entrance to the trial;\r\n* If sites received CT and/or MR images from institutions other than their own, ACRIN recommends a re-read by a local neuroradiologist to ensure compliance with protocol eligibility requirements
Able and amenable to baseline and follow-up PET/computed tomography (CT) imaging and study-specific biopsy procedures\r\n* Note: If there are any imaging concerns that the patient may not be suitable for quantitative PET/CT (e.g., a metallic device directly overlies the breast), discussion with the local and central radiologists is required to confirm eligibility for the trial; also, it is expected that subjects have all PET/CT imaging done on pre-qualified machines for the study; if baseline imaging done on another machine, please contact the Protocol Chair/designee for guidance prior to confirming eligibility
OVARIAN CANCER PARTICIPANTS: Patients with contraindications for PET/CT or who cannot complete a PET/CT scan or other study procedures
BREAST CANCER PARTICIPANTS: Patients with contraindications for PET/CT or who cannot complete a PET/CT scan or other study procedures
Patients who cannot undergo PET/CT scanning (i.e. because of weight limits, claustrophobia)
PET/MR or PET/CT is not able to be scheduled within  hours of radioembolization
Patients tumor(s) must be FDG avid on baseline standard of care FDG-PET/CT or PET/MR imaging that was performed at Barnes-Jewish Hospital Clinical PET Facility
If the patient will be scanned on the PET/MR for the mid-treatment scan, they must be determined to be safe for exposure to the magnetic field; this will be determined the day of imaging by the technologist with the use of a screening form; if a patient is not safe for the PET/MR scanner, their mid-treatment images will occur on the PET/CT scanner in the Center for Clinical Imaging Research
Patients may not have received trastuzumab within  weeks of projected Cu-DOTA-trastuzumab/PET-CT
Unable to cooperate for PET/CT
At least  measurable site of disease on cross-sectional imaging (CT/PET)
Patients must have disease with FDG-PET/CT avidity
Patients who cannot undergo PET/CT scanning (i.e. because of weight limits)
Any contraindications to PET/CT or lymph node mapping (inability to control serum glucose to a value of =<  mg/dl for fludeoxyglucose F- [FDG]-PET/CT)
OR a suspected low-grade brain tumor, where confirmation is based upon a combination of other imaging (e.g. PET/CT, MRI, diagnostic CT) and clinical assessment.
The time interval between F-FSPG PET/CT and other imaging (including other PET/CTs, MRI or diagnostic CT) should be within  weeks (exceptions will be allowed for  weeks, if there are no other options)
No chemotherapy, radiotherapy, or immune/biologic therapy scheduled or performed between other imaging (PET/CTs, MRI, or diagnostic CTs) andF-FSPG PET/CT.
Any biopsy proven HER-positive malignancy; American Society of Clinical Oncology (ASCO) guidelines will be used to define HER-positivity for breast cancer; similar guidelines will be used for other cancer types as appropriate; at least one malignant lesion on CT, magnetic resonance (MR), or fludeoxyglucose (FDG) PET/CT within  days of protocol enrollment
Patients who cannot undergo PET/CT scanning because of weight limits; PET/CT scanners may not be able to function with patients over  pounds
Patients should have no contraindications for FDG-PET/CT
Patients with bone metastases on PET/CT
Patients without bone metastases on PET/CT
Time between the diagnostic CT and PET/CT will be no more than  days with no intervening treatment to ensure that any differences found between the exams are related to imaging technique and not a change in disease
Patient will be undergoing a FDG-PET scan as part of staging or response assessment for malignancy; Note: the patient may be newly-diagnosed, currently receiving therapy, or have already completed therapy; the presence of identifiable tumor on the PET scan is not required
Radiotherapy, chemotherapy or any investigational agent within the previous  weeks of administrating F-PEG-IPQA for PET/CT imaging
A non-investigational targeted agent within the previous  weeks of F-PEG-IPQA for PET/CT imaging
Thoracic or abdominal surgery within the previous  weeks of F-PEG-IPQA for PET/CT imaging
Patients with contraindications for PET/CT or who cannot complete a PET/CT scan
BIODISTRIBUTION COHORT: At least one lesion >= . cm that is seen on standard imaging (e.g. CT, magnetic resonance imaging [MRI], ultrasound, fludeoxyglucose F- [FDG] PET/CT)
DYNAMIC COHORT: At least one lesion >= . cm that is seen on standard imaging (e.g. CT, MRI, ultrasound, FDG PET/CT)
